Scenic Biotech of the Netherlands has inked its first deal with a big pharma, signing a multi-year collaboration with Roche Holding AG's Genentech unit which represents a major validation of the company's strategy of identifying genetic modifiers to treat diseases.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?